Curis (CRIS) Competitors $1.84 +0.09 (+5.14%) Closing price 01:59 PM EasternExtended Trading$1.78 -0.06 (-2.99%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. DOMH, ACHV, FBIO, SABS, BOLT, MTEM, AMGN, GILD, VRTX, and REGNShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Dominari (DOMH), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry. Curis vs. Its Competitors Dominari Achieve Life Sciences Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Curis (NASDAQ:CRIS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Which has more volatility & risk, CRIS or DOMH? Curis has a beta of 3.6, meaning that its stock price is 260% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Do analysts recommend CRIS or DOMH? Curis currently has a consensus target price of $17.00, suggesting a potential upside of 823.91%. Given Curis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Curis is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CRIS or DOMH more profitable? Dominari has a net margin of -167.73% compared to Curis' net margin of -376.08%. Curis' return on equity of 0.00% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Curis-376.08% N/A -97.14% Dominari -167.73%-91.67%-77.80% Which has stronger earnings & valuation, CRIS or DOMH? Dominari has higher revenue and earnings than Curis. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCuris$10.91M1.76-$43.39M-$6.23-0.30Dominari$18.15M4.25-$14.70M-$4.50-1.17 Does the media prefer CRIS or DOMH? In the previous week, Curis had 1 more articles in the media than Dominari. MarketBeat recorded 1 mentions for Curis and 0 mentions for Dominari. Curis' average media sentiment score of 0.00 equaled Dominari'saverage media sentiment score. Company Overall Sentiment Curis Neutral Dominari Neutral Do insiders & institutionals hold more shares of CRIS or DOMH? 30.0% of Curis shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 5.5% of Curis shares are owned by company insiders. Comparatively, 33.0% of Dominari shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryDominari beats Curis on 8 of the 15 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.31M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.3021.5627.4020.04Price / Sales1.76281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book-2.597.518.085.67Net Income-$43.39M-$55.05M$3.16B$248.47M7 Day Performance-17.12%3.16%2.12%2.90%1 Month Performance-20.00%5.92%4.43%5.75%1 Year Performance-70.56%5.82%35.62%21.36% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.3755 of 5 stars$1.84+5.1%$17.00+823.9%-72.0%$18.31M$10.91M-0.3060News CoverageDOMHDominari0.3893 of 5 stars$5.44-2.0%N/A+163.8%$81.27M$18.15M0.004Positive NewsACHVAchieve Life Sciences1.6177 of 5 stars$2.26+1.3%$14.33+534.2%-50.8%$77.35MN/A-1.6920High Trading VolumeFBIOFortress Biotech2.1672 of 5 stars$1.86+2.2%$21.00+1,029.0%+9.6%$53.82M$57.67M-0.83170Gap UpSABSSAB Biotherapeutics3.6079 of 5 stars$1.76+3.8%$13.25+655.0%-38.8%$15.70M$1.32M0.00140Positive NewsGap UpBOLTBolt Biotherapeutics3.0099 of 5 stars$5.77+2.9%$50.00+766.6%-59.8%$10.75M$7.69M-0.1790News CoveragePositive NewsHigh Trading VolumeMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.4477 of 5 stars$279.21+0.8%$307.82+10.2%-4.5%$149.01B$33.42B25.4828,000Positive NewsGILDGilead Sciences4.8434 of 5 stars$110.87+0.2%$110.55-0.3%+63.0%$137.67B$28.75B23.3417,600Positive NewsInsider TradeVRTXVertex Pharmaceuticals4.6743 of 5 stars$445.20+0.9%$511.62+14.9%-3.5%$113.32B$11.02B-113.576,100Positive NewsREGNRegeneron Pharmaceuticals4.9535 of 5 stars$525.00+0.8%$813.57+55.0%-47.6%$56.25B$14.20B13.3715,106Trending NewsAnalyst Downgrade Related Companies and Tools Related Companies Dominari Competitors Achieve Life Sciences Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
